Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to describe the long-term safety of a fixed combination product containing an alternative preservative, dosed once daily for 12 months, in patients with open-angle glaucoma or ocular hypertension.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Cloprostenol; Maleic acid; Timolol; Travoprost

Criteria

Inclusion Criteria:

• Willing and able to sign an informed consent document.

• Open-angle glaucoma or ocular hypertension who would benefit from a fixed combination medication, in the opinion of the investigator.

• Stable treatment of an IOP-lowering medication.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Pregnant, breastfeeding, or not using adequate birth control.

• Best-corrected visual acuity (BCVA) worse than 55 ETDRS letters.

• Other protocol-defined exclusion criteria may apply.